L&K Biomed Establishes Next-Generation Expandable Cage in US Market

LN C Spine Achieves 1.7 Billion KRW Sales with Passlock-TM

[Asia Economy Reporter Hyungsoo Park] Spine implant company L&K Biomed announced on the 20th that its height-expandable cage ‘PassLock-TM,’ approved by the US FDA in March this year, has quickly established itself in the market.

A representative of L&K Spine, the US subsidiary of L&K Biomed, said, "Generally, in the US, a new product is used in at least 100 surgeries before its marketability and product performance are recognized, with comprehensive evaluation of malfunctions, complications, and prognosis."

PassLock-TM was recognized for its quality after being used in 122 surgeries within six months of its launch.

As of the first half of this year, the US accounted for 75% of L&K Biomed’s total sales. Of the 8.3 billion KRW in sales during the first half, 6.25 billion KRW was generated in the US. To expand the US market, in May, the sales agency rights held by the existing distributor Aegis Spine were transferred to the newly established US subsidiary L&K Spine.

From May to this month, L&K Spine achieved approximately 1.7 billion KRW in sales solely from the new height-expandable cage product ‘PassLock-TM.’

The height-expandable cage PassLock-TM is a posterior and posterolateral insertion type product, which is the most frequently used in procedures. For expandable products, the accuracy and ergonomic adjustment of the implant height are crucial. PassLock-TM can increase the angle up to 20 degrees during spinal surgery. It is highly competitive due to its adjustable length options.

Park Geun-joo, CEO of L&K Biomed, introduced, "The new height-expandable cage PassLock-TM has recently received positive evaluations from US hospital doctors, who report no malfunctions or postoperative complications during spinal surgeries, expressing satisfaction with the product."

This content was produced with the assistance of AI translation services.